Profound Medical (PROF) announces that the first commercial benign prostatic hyperplasia, BPH, treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical Partners with NFL Legend Leonard Wheeler to Promote TULSA-PRO
- Profound Medical enters agreement with former NFL player Leonard Wheeler
- Profound Medical Corp. Announces Successful Shareholder Meeting Outcomes
- Profound Medical’s Earnings Call Highlights Growth and Innovation
- Profound Medical downgraded to Outperform from Strong Buy at Raymond James